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Although somatic mutations in a number of genes have been associated with development of human tumors, such
as lipomas, relatively few examples exist of germline mutations in these genes. Here we describe an 8-year-old boy
who has a de novo pericentric inversion of chromosome 12, with breakpoints at p11.22 and q14.3, and a phenotype
including extreme somatic overgrowth, advanced endochondral bone and dental ages, a cerebellar tumor, and
multiple lipomas. His chromosomal inversion was found to truncate HMGA2, a gene that encodes an architectural
factor involved in the etiology of many benign mesenchymal tumors and that maps to the 12q14.3 breakpoint.
Similar truncations of murine Hmga2 in transgenic mice result in somatic overgrowth and, in particular, increased
abundance of fat and lipomas, features strikingly similar to those observed in the child. This represents the first
report of a constitutional rearrangement affecting HMGA2 and demonstrates the role of this gene in human growth
and development. Systematic genetic analysis and clinical studies of this child may offer unique insights into the
role of HMGA2 in adipogenesis, osteogenesis, and general growth control.
HMGA2 (MIM 600698) encodes an architectural factor
belonging to the high-mobility group (HMG) of proteins
involved in the pathogenesis of a variety of benign mes-
enchymal tumors, including uterine leiomyomas, pul-
monary chondroid hamartomas, fibroadenomas, pleo-
morphic salivary gland adenomas, and lipomas (Sandros
et al. 1990; Sreekantaiah et al. 1991; Bullerdiek et al.
1993; Schoenberg Fejzo et al. 1995; Kazmierczak et al.
1996). HMG proteins alter chromatin architecture and
thus participate in the regulation of gene expression.
Exons 1–3 encode AT hook domains that bind to the
minor groove of AT-rich DNA. The remaining two ex-
ons encode an acidic carboxy terminus, which is of un-
known function but has been hypothesized to confer
specificity. DNA binding by HMGA2 induces confor-
mational changes in the double helix, allowing forma-
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tion of transcriptional complexes that, in turn, can either
promote or inhibit transcription (Reeves and Becker-
bauer 2001).
In vivo data have provided additional biological evi-
dence for the function of HMGA2. Mice with homo-
zygous Hmga2 disruption are born with diminished
body size and extremely decreased fat levels (Zhou et
al. 1995), whereas mice expressing a truncated Hmga2,
including only the first three exons under the regulatory
control of the cytomegalovirus (CMV) promoter, de-
velop gigantism and lipomatosis (Battista et al. 1999).
Expression of a similarly truncated Hmga2 construct
under the control of the murine major histocompatibility
complex class I H-2Kb promoter gives rise to mice with
increased adipose levels and an unusually high frequency
of lipomas (Arlotta et al. 2000). Together, these in vivo
studies suggest a role for HMGA2 in adipose metabolism
and especially in lipomagenesis.
DGAP103 is an 8-year-old boy with a pericentric
inversion of chromosome 12, inv(12)(p11.22q14.3),
whose phenotype includes postnatal onset of extreme
somatic overgrowth, advanced endochondral bone and
dental ages with megaepiphyseal dysplasia, and multiple
subcutaneous lipomas. Other features include persistent
Reports 341
thrombocytopenia, arthritis, brachydactyly, a stable cer-
ebellar tumor, and facial dysmorphism.
The boy was born at full term, by vaginal delivery, to
a 26-year-old gravida 2, para 1–2 woman and an un-
related 25-year-old man. The pregnancy was compli-
cated by premature labor at 30 wk gestation, requiring
terbutaline administration through 34 wk of gestation.
Birth parameters included weight of 3,267 g (25th–50th
percentiles) and length of 49.5 cm (25th–50th percen-
tiles). No anomalies were noted at birth, and the boy
had an uneventful neonatal course with mild jaundice
that did not require treatment. However, he was referred
for genetic evaluation at 9 mo of age for steadily in-
creasing growth parameters, with height, weight, and
occipital-frontal circumference all at or above the 95th
percentile. In addition to developing mildly dysmorphic
facial features and brachydactyly (fig. 1A), he was noted
to have bilateral lower extremity subcutaneous nodules
(fig. 1B). Biopsy of one of these nodules showed mature
adipocytes and fibrovascular tissue (fig. 1C). Findings
suggestive of a skeletal dysplasia included bowing of the
lower extremities, rhizomelic shortening, and progres-
sive joint enlargement with some reduced range of mo-
tion. Radiologic studies at 1, 4, and 8 years of age re-
vealed flared, enlarged epiphyses with shortened long
and tubular bones and advanced endochondral bone age
(fig. 1D, 1E, and 1J). Additional skeletal abnormalities
included megaepiphyseal dysplasia with platyspondyly
(not shown); shortened, broad metacarpals; and rhizo-
melic shortening, as confirmed by the International Skel-
etal Dysplasia Registry (Cedars-Sinai Medical Center,
Los Angeles). He developed premature dentition, with
upper incisors erupting at age 3 mo and eight teeth pre-
sent by 5 mo; a panoramic dental X-ray at 4 years of
age showed advanced dental age, with enlarged and pos-
sibly supernumerary teeth (fig. 1G). Because of concerns
of macrocephaly, he underwent cranial imaging at 27
mo of age. Magnetic resonance imaging revealed a right
cerebellar lesion measuring 2 cm, located ventral to the
cerebellar nuclei (fig. 1F). On the basis of the imaging
studies, the differential diagnosis included hamartoma
and low-grade cerebellar glioma. Motor and sensory ex-
ams showed normal results. The brain lesion has been
followed by use of serial imaging and has not pro-
gressed by age 8 years; because the mass appeared
stable, biopsy was not performed. Furthermore, mild
thrombocytopenia and leukopenia (with platelet counts
as low as 60,000) were noted at age 5 years, at which
time a bone marrow biopsy was performed that
showed trilineage hematopoiesis with mildly reduced
cellularity but no evidence of malignancy. Cytogenetic
analysis of the bone marrow biopsy was reported as
46,XY,inv(12)(p12.2q15) (fig. 2A). The same cytoge-
netic result was observed independently when peripheral
blood and lipoma specimens were analyzed, confirming
this rearrangement to be constitutional in nature.
On most recent evaluation, at 8 years of age, the pa-
tient’s growth parameters were remarkable for extreme
overgrowth, with stature of 169 cm (50th percentile for
a 15-year-old boy), weight of 50.9 kg (50th percentile
for a 14-year-old boy), and head circumference of 56
cm (50th percentile for an adult male). Limited range of
motion was noted for the knees, ankles, wrists, and fin-
gers, most likely secondary to markedly enlarged epiph-
yses. He had brachydactyly of hands and feet, as well
as shortened distal phalanges and curved, redundant
nails (fig. 1I). Partial flexion contractures were present
in the fingers, and the lower legs were bowed bilaterally.
He reported arthritic symptoms that became especially
severe during the winter. Bone age was advanced and
was equivalent to that of a 13.5-year-old male, with no
evidence of epiphyseal closure (fig. 1J). Progressive cran-
iofacial dysmorphism also was observed and included
flat supraorbital ridges, ocular hypertelorism, upslanting
narrow palpebral fissures, large ears with prominent an-
tihelices, prominent nasal bridge with anteverted nares,
hypertrophy of alveolar ridges with inability to close the
mouth, and retrognathia (fig. 1H). Several gooseflesh-
like, hypopigmented lesions were present on the lower
segments of the upper extremities and on the face, as
well as prominent papillae on the tongue; these lesions
appeared to be transient over several examinations. The
visible lipomas became less prominent, and their number
appeared to diminish over the course of progressive eval-
uations. At this same examination, peripheral blood was
analyzed for levels of total and ionized calcium, vitamin
D, phosphate, alkaline phosphate, parathyroid hor-
mone (PTH), and associated receptor (PTHrP; data not
shown). Levels of each of these analytes were considered
to be within normal physiological limits.
Breakpoint mapping studies were undertaken to fine
map the chromosomal rearrangement, using FISH and
other molecular methods. For this purpose, a peripheral
blood specimen was collected after informed consent
was obtained, in accordance with institutional policies
and procedures for human research at Partners Health
Care System. Cell transformation was performed at the
Massachusetts General Hospital Cell Transformation
Core, using standard protocols. Transformed lympho-
blastoid cells were then cultured to generate sufficient
material for GTG banding, FISH mapping, and nucleic
acid extraction using standard protocols (see below).
Metaphase chromosome spreads were prepared using
standard cytogenetic protocols (Ney et al. 1993). FISH
was performed with direct-labeled cosmid or BAC
probes to map each inversion breakpoint. BAC clones
were selected using the University of California–Santa
Cruz (UCSC) Genome Browser (May 2004 freeze) and
were hybridized in differentially labeled pairs (Spectrum
Figure 1 Clinical features of DGAP103. A, Facial features at age 27 mo, showing macrocephaly, flat supraorbital ridges, widely spaced
eyes, and prominent alveolar ridges. B, Bilateral bowing and multiple lipomas on lower extremities at age 27 mo. C, Hematoxylin- and eosin-
stained tissue sections of right lateral leg subcutaneous soft-tissue mass (biopsied at age 14 mo) confirms a benign lipoma comprised of mature
adipocytes and paucicellular collagen. D, Megaepiphyseal flaring of the femur and tibia at the knee joint at 1 year of age. E, Broad distal ulna
and radius with enlarged epiphyses (arrows) at 4 years of age. Advanced bone age is indicated by initial ossification of the trochlea of the ulna
(arrowhead) which occurs, on average, at ∼7 years of age). F, Cerebellar mass in the right cerebellar hemisphere (arrow). G, Disorganization
and advanced dental age evident both for erupted and unerupted teeth on panoramic dental X-ray taken at 4 years of age. H, Facial features
with more severe flattening of supraorbital ridges, narrow eye openings, prominent ears with protruding antihelix, and significant gumhypertrophy
with recessed mandible at 8 years of age. I, Brachydactyly and enlarged interphalangeal joints with joint restriction at 8 years of age. J, Advanced
bone age of 13.5 years, without evidence of epiphyseal closure, on wrist radiograph taken at 8 years of age.
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Figure 2 FISH mapping of chromosome 12 breakpoints. A, Idi-
ograms for normal chromosome 12 (left) and inverted homolog (right)
showing inv(12)(p11.22q14.3). B, Representative hybridization pat-
tern following FISH with BAC clone RP11-677M24, which maps to
band q14.3 on chromosome 12 and spans the long (q) arm breakpoint.
One green signal is present on the normal chromosome 12, whereas
two green signals can be seen on the inverted homolog (arrow indicates
signal translocated to the short arm by the inversion). C, 12q14.3
breakpoint mapping. Initial FISH mapping of the 12q14.3 breakpoint
showed that cosmids 142H1 and 27E12 flank the breakpoint, placing
it between exons 2 and 4 of HMGA2. BAC RP11-677M24 was split
in the inverted chromosome 12, narrowing the breakpoint region to
an ∼19.5-kb interval. D, 12p11.22 breakpoint mapping. BAC CTD-
2308H7 is split by the inversion. No genes are known to be disrupted
by this breakpoint. Potential candidate genes and their respective dis-
tances from the 12p11.22 breakpoint are indicated.
Green and Spectrum Red or Orange [Amersham]). At
least 10 metaphases were scored per hybridization. FISH
was performed initially with cosmid clones 142H1 and
27E12 at the HMGA2 locus (Schoenmakers et al. 1995).
In a structurally normal chromosome 12, HMGA2 is
oriented at 12q14.3 from centromere (5′) to telomere
(3′). Cosmid 27E12, which includes the last two exons
of HMGA2, remained on the chromosome 12 long arms
of both the normal and the inverted homologs (fig. 2C),
indicating that the breakpoint was distal to this clone.
In contrast, signals corresponding to cosmid 142H1,
which includes exons 1 and 2 of HMGA2, were trans-
posed to the short arm of the inverted chromosome 12,
indicating an intragenic rearrangement of HMGA2. Suc-
cessive FISH experiments were then performed using
BAC clones to refine this breakpoint further. The hy-
bridization of two BAC clones (RP11-677M24 and
RP11-462A13) was split on the inverted homolog (fig.
2B). As a result, the 12q breakpoint was narrowed to
an interval flanked by BAC clones RP11-366L20 (defin-
ing the distal boundary) and RP11-677M24, for which
the signal was split between the short and long arms
(defining the proximal boundary) (fig. 2B and 2C). This
refined interval flanking the long arm breakpoint was
∼19.5 kb. On the basis of our FISH mapping data, one
of the bands involved in this break was reassigned to
q14.3, rather than to q15, as defined by initial GTG
banding.
Mapping of the short arm breakpoint was accom-
plished by similar, successive BAC hybridizations. As
diagrammed in figure 2D, this breakpoint interval was
narrowed to a region of ∼19.5 kb flanked by clones
CTD-2308H7, which was split by the inversion, and
RP11-954D8 (not shown), which was present on the
long arm. On the basis of this set of FISH mapping
experiments, the short arm breakpoint was reassigned
to p11.22, rather than to p12.2. Interestingly, the UCSC
Genome Browser indicates relatively few known or pu-
tative genes in the 12p11.22 region. PTX1, which en-
codes a nuclear protein down-regulated in prostate
carcinoma (fig. 2D), and ARG99, which encodes an
UDP-N-acetylglucosamine-peptide N-acetylglucosami-
nyl-transferase 110-kDa subunit, map within the same
cytogenetic band but centromeric to the breakpoint
(∼426 kb and ∼589 kb away, respectively) (fig. 2D), as
do sequences for the hypothetical protein AF113698
(∼64 kb away); hypothetical protein FLJ11088 maps
∼228 kb telomeric to the breakpoint. The only known
gene in 12p11.22 with a corresponding entry in the Pro-
tein Data Bank is PTHRP (parathyroid hormone–related
peptide, also known as “PTHLH” or “parathyroid hor-
mone–like hormone” [MIM 168470]). At a distance of
∼806 kb telomeric to the 12p11.22 breakpoint, it is pos-
sible that a fusion product would form between exons
1–3 of HMGA2 and PTHRP (both transcribed centro-
mere to telomere); however, no such fusion product was
detected using specific HMGA2-PTHRP primers and 3′
rapid amplification of cDNA ends (RACE) (data not
shown). Furthermore, no known genes map directly
within BAC CTD-2308H7, suggesting that disruption
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Figure 3 Molecular analyses. A, Southern blot analysis refines the 12q14.3 breakpoint within HMGA2 to a 2,115-bp interval that maps
within intron 3. This intron is a frequent target of disruption in mesenchymal tumors. B, Northern blot analysis performed using a cDNA
probe against the entire HMGA2 coding sequence identifies a wild-type 4.1-kb transcript in total RNA from lymphoblastoid cells established
from DGAP103 (right) and control (left) peripheral blood specimens.
of a specific gene at 12p11.22 is unlikely to contribute
to the phenotype of our patient.
Southern blot analysis was initiated to refine the data
generated by FISH. Total genomic DNA was isolated
from DGAP103 and control lymphoblastoid cells by use
of the PureGene DNA isolation kit (Gentra Systems).
Restriction enzymes BclI and XbaI were used indepen-
dently to digest 8 mg of DNA. Digested DNA was elec-
trophoresed in a 1% agarose gel, transferred onto Ny-
lon-N membrane (Amersham), and crosslinked using
a Stratalinker (Stratagene). For probe preparation, prim-
ers were designed to amplify DNA within the overlap-
ping region between these two fragments. These in-
cluded primers 103-4Lb (5′-TGAACATGGCCATCTC-
TGTG-3′) and 103-4Rb (5′-CAGAGCCTACCATTGT-
CTTGG-3′). The resulting 707-bp amplicon was labeled
with 32a-dCTP using the MegaPrime DNA labeling mix
(Amersham). Digestion with the restriction enzyme XbaI
identified a novel fragment (fig. 3A) and refined the
breakpoint interval to a 2,115-bp segment within the
third intron of HMGA2.
By use of standard protocols (Sambrook and Russell
2001), northern blot analysis was performed to test
for expression of aberrant transcripts. A full-length
HMGA2 cDNA clone (kindly provided by B. Kaz-
mierczak) was used as a probe against total RNA iso-
lated from lymphoblastoid cultures established from
DGAP103 and from a control lymphoblastoid sample.
From this nonquantitative analysis, a 4.1-kb band rep-
resenting the wild-type transcript (fig. 3B) was observed
in both samples, as was a faint and slightly smeared band
(∼10 kb) in the RNA from DGAP103 (not shown). Al-
though it is possible that this larger product represents
a fusion transcript, detection of a run-on transcription
product cannot be excluded. However, repeated at-
tempts at 3′ RACE performed by use of a poly-T primer
for first-strand synthesis were unsuccessful at amplifying
any product (data not shown). To assess quantitative
differences in HMGA2 expression, real-time PCR was
performed by use of an iCycler Optical System (Bio-
Rad), with total RNA derived from DGAP103 lympho-
blasts and control lymphoblasts without rearrangement
affecting chromosome 12 (data not shown). Primers
selected included 5′-AGTCCCTCTAAAGCAGCTCAA-
AAG-3′, within exon 2 of HMGA2, and 5′-GCCATT-
TCCTAGGTCTGCCTC-3′, within exon 3. The probe,
5′-AGAAGCCACTGGAGAAAAACGGCCA-3′, was la-
beled with 5′-FAM/3′-BHQ-1 (Biosearch Technologies)
and is within the amplified sequence. Expression levels
were determined from an average of triplicate readings,
by use of the same sample preparation. This analysis
indicated slightly increased levels of the 5′ RNA tran-
script, including exon 3, in DGAP103, relative to the
levels in the control. Specifically, lymphoblasts from
DGAP103 had a relative HMGA2 expression level of
1.4 times that in the control.
Of individuals with balanced de novo chromosomal
rearrangements, ∼6% are born with anatomical, bio-
chemical, developmental, or behavioral abnormalities,
some of which will be attributable to disruption of
genes critical to growth and development. In analysis of
DGAP103, the unusual phenotype and constitutional
chromosomal inversion implicated a gene, HMGA2,
that is known to be involved in both normal and path-
ologic development of mesenchymal tissues. On the basis
of the hypothesis that HMGA2 involvement was likely,
FISH mapping and Southern blot analysis of the 12q14.3
region were used to confirm and narrow the suspected
HMGA2 breakpoint to an ∼2-kb interval within the
∼140-kb third intron. Involvement of a gene at the
12p11.22 breakpoint region, either directly or by po-
sition effect, was not detected and seems unlikely.
Because DGAP103 developed numerous lipomas on
his lower extremities and because of the known role of
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HMGA2 in lipomagenesis, discovery of a constitutional
disruption of HMGA2 became especially relevant. Li-
pomas are one of the most common neoplasms in hu-
mans, and rearrangement of HMGA2 in these and other
mesenchymal tumors is well established (Sreekantaiah
et al. 1991; Fedele et al. 2001). Approximately 50% of
lipomas are karyotypically abnormal, and, of those, the
most frequently rearranged region involves chromosome
12q14-q15 (Ashar et al. 1995); both translocations and
inversions have been described (Mitelman Database of
Chromosome Aberrations in Cancer).
Somatic rearrangements of HMGA2 may result in sev-
eral different forms of gene disruption and, subsequently,
different forms of transcripts. Intragenic disruption of
HMGA2 in mesenchymal tumors has been shown to
involve formation of chimeric transcripts. For lipomas
in particular, these partner genes include LPP, a gene
with highly conserved LIM motifs that are active in a
variety of developmentally regulated processes (Freyd
et al. 1990). Chimeric HMGA2 gene products are un-
common among uterine leiomyomata and other gener-
ally nonlipomatous mesenchymal tumors (Quade et al.
2003). Interestingly, in vitro experiments demonstra-
ted that either truncated HMGA2 (exons 1–3) or an
HMGA2 fusion (HMGA2-LPP) can transform NIH 3T3
murine fibroblasts (Fedele et al. 1998). It is possible,
therefore, that HMGA2 contributes to tumorigenesis
following either type of structural alteration. Although
some data support a role in regulation of cellular pro-
liferation, the specific contribution of either truncated
or chimeric HMGA2 transcripts to tumorigenesis is un-
known. For DGAP103, it is likely that the lipomatous
lesions noted are due to disruption of HMGA2.
The genomic structure of HMGA2 includes an ex-
tremely large third intron (∼140 kb) that has been de-
scribed as the most frequent target of cytogenetic rear-
rangements in human neoplasms (Kazmierczak et al.
1998). Several HMGA2 rearrangements mapping within
intron 3 have been described in detail (Ashar et al. 1995;
Schoenmakers et al. 1995); thus, we speculated initially
that the breakpoint would map there. If so, the chro-
mosomal inversion in DGAP103 would result in trans-
location of the first three DNA-binding domain exons
to the short arm of chromosome 12. Indeed, both FISH
and Southern blotting confirmed that the breakpoint
mapped within intron 3 and that it separated the three
DNA-binding AT hook domains from the acidic carboxy
terminus of the protein encoded by exons 4 and 5.
Constitutional disruption of HMGA2 could contrib-
ute to the phenotype in DGAP103 through a number of
different mechanisms. First, formation of a fusion tran-
script between the 5′ end of HMGA2 and the 3′ portion
of another gene, similar to what has been observed in
lipomas, might favor a gain-of-function mechanism with
a novel function or altered specificity of the chimeric
protein. This scenario, however, is not supported by our
data. Notably, a prospective fusion partner within a
plausible distance and in the correct orientation relative
to the breakpoint on the short arm of chromosome 12
was not identified. Furthermore, 3′ RACE experiments
did not identify any chimeric transcripts (data not
shown). In a second model, expression of a truncated
HMGA2 allele could create a dysregulated protein with
novel function or altered specificity related to the de-
velopmental abnormalities in DGAP103. Although anal-
ysis by northern blotting and real-time PCR did not de-
tect such a truncated transcript in lymphoblast RNA
(i.e., derived from B cells), we cannot exclude the pos-
sibility that a truncated HMGA2 transcript might not
be expressed stably in lymphoblasts, the only cell type
available for testing. A third potential mechanism is up-
regulation of the wild-type allele following disruption of
the translocated allele (Tkachenko et al. 1997; Ashar et
al. 2003). HMGA2 transcript abundance, measured by
northern blotting and real-time PCR in RNA from the
DGAP103 lymphoblastoid cell line, was slightly elevated
in DGAP103 compared with a control. The full-length
transcript detected by northern blot analysis presumably
is attributed to the normal allele. In this scenario, it is
possible that a compensatory response might up-regulate
HMGA2 expression in other tissues.
Battista and coauthors (1999) reported that expres-
sion of a truncated murine Hmga2 induced gigantism
associated with lipomatosis. In these transgenic animals,
expression of only the first three exons of Hmga2 was
driven by the CMV promoter. By 12 mo of age, these
mice showed an average 15% increase in body length
and a 36% weight gain compared with wild-type litter-
mates. An expansion of retroperitoneal adipose tissue
was observed, consistent with a role for Hmga2 in mu-
rine lipoma development. The authors proposed that
disruption of Hmga2 led to up-regulation of the gene
and subsequent stimulation of adipogenesis. No ab-
normalities of the skeletal system or dentition were
described.
Subsequently, Arlotta and coauthors (2000) described
transgenic mice expressing a truncated Hmga2 (also
lacking the carboxy terminus) driven by the H-2Kb pro-
moter. Although lipomas are exceedingly common in
humans, they rarely arise spontaneously in mice (Arlotta
et al. 2000). Therefore, it was significant when a high
frequency of lipomas was seen, lending further support
to a role for truncated Hmga2 in adipocyte growth. As
in the model reported above, no abnormalities of the
skeletal system or dentition were described.
In contrast to murine models with overexpression of
the three AT hook domains, Hmga2/mice demonstrate
the “pygmy” phenotype, in which dramatic reductions
in body fat and small stature are hallmark features
(Zhou et al. 1995). Hmga2/ mice are resistant to diet-
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induced obesity, and reduction of Hmga2 expression
protects mice from leptin-deficiency–induced obesity
(Anand and Chada 2000). This transgenic model differs
from the genotype in our patient in that haploinsuffi-
ciency fails to eliminate HMGA2 expression, suggesting
a different mechanism of altered expression underlying
the DGAP103 phenotype. To date, HMGA2 function
has not been associated with regulation of any of the
known somatic overgrowth genes, underscoring the need
for further study of its role in growth.
These murine models support a role for HMGA2 in
adipogenesis and implicate expression of the truncated
HMGA2 in the appearance of numerous lipomas and
somatic overgrowth in our patient. However, some of
the other clinical features may also be explained simply
by HMGA2 disruption. For example, the stable right-
sided cerebellar mass and the prominent tongue papil-
lomas may represent benign hamartomatous lesions,
analogous to those described in other overgrowth con-
ditions such as Cowden/Bannayan-Riley-Ruvalcaba syn-
drome (MIM 158350 and MIM 153480) and Proteus
syndrome (MIM 176920) (Eng 2003).
Low-level expression of HMGA2 has been demon-
strated in a few human adult tissues (e.g., lung and
kidney), but more-abundant levels of transcript exist in
certain tissues, primarily during embryonic and fetal de-
velopment (Gattas et al. 1999). HMGA2 has been
shown to be expressed in hematopoietic stem cells and
in certain leukemias (Rommel et al. 1997; Santulli et al.
2000). Andrieux and coauthors (2004) observed rear-
rangements of 12q13-15 in the hematopoietic cells of
patients with a chronic myeloproliferative disorder (my-
elofibrosis with myeloid metaplasia) and proposed that
dysregulation and increased expression of HMGA2 in
myeloid progenitor cells may contribute to disease. Fur-
thermore, extragenic rearrangement of HMGA2 also has
been reported in acute lymphocytic leukemia (Pierantoni
et al. 2003). Both studies raise the question of the role
HMGA2 might play in normal hematopoiesis and, by
extension, the role of HMGA2 in the chronic throm-
bocytopenia and neutropenia in DGAP103.
Moreover, Broberg and coauthors (1999, 2001)
showed that a rearranged HMGA2 is expressed in the
synovia of patients with osteoarthritis; these rearrange-
ments seem to occur without any known propensity
for mesenchymal tumor formation at the growth plate.
Therefore, it is possible that disruption of HMGA2
may also play a role in mesenchymal hyperplasia rather
than being restricted uniquely to the neoplastic process.
HMGA2 rearrangements have recently been reported in
bone and soft-tissue tumors, a subset of which express
only a truncated HMGA2 transcript (exons 1–3) (Dah-
len et al. 2003). Abnormal HMGA2 expression may be
the cause of epiphyseal overgrowth in DGAP103, and,
although we cannot exclude the possibility that his ar-
thritis arose as a secondary effect of enlarged epiphyses,
this documented expression pattern of HMGA2 in syn-
ovial tissues also raises the possibility that aberrant
HMGA2 expression is a contributing factor to the joint
pain.
The complete phenotype of DGAP103 need not be
explained entirely by disruption of HMGA2, and anal-
ysis of the second inversion breakpoint could confer in-
sight into potential genetic causes for the remainder of
the clinical features. However, the split BAC clone (CTD-
2308H7) identified at the p11.22 breakpoint included
no known genes, a finding consistent with our inability
to identify a rearrangement partner for HMGA2 by 3′
RACE. This observation also supports the hypothesis
that truncation of HMGA2, rather than fusion with a
novel sequence, could be responsible for dysregulating
this gene.
In an effort to consider a role for position effect, we
analyzed the annotated genomic sequence for a distance
of 1 Mb on either side of the p11.22 inversion break-
point. Centromeric to the p11.22 breakpoint is PTX1,
which has a postulated role in prostate cancer is but
unlikely to be involved in the current phenotype (Kwok
et al. 2001). In the 1-Mb interval telomeric to the p11.22
breakpoint, only a single gene corresponded to a known
protein product: PTHLH (i.e., PTHRP). The protein
encoded by PTHRP, parathyroid hormone–related pep-
tide (MIM 168470), is involved in regulation of endo-
chondral bone development and epithelial-mesenchymal
interactions, and it signals specifically through the par-
athyroid hormone receptor (PTHR1). Mice homozygous
for a null mutation in PTHRP show abnormalities of
endochondral bone development, including premature
maturation of chondrocytes and accelerated bone for-
mation similar to that observed in some forms of a
dwarfing chondrodysplasia (Karaplis et al. 1994). Un-
fortunately, there is no existing animal model for
overexpression of PTHRP to allow comparison of
phenotypes.
PTHRP maps at a great distance from the p11.22
inversion breakpoint, and its currently recognized ge-
nomic structure is not disrupted by the rearrangement.
However, there is precedence for position effect act-
ing over comparable distances (∼806 kb between the
p11.22 breakpoint and PTHRP). SOX9, a gene involved
in campomelic dysplasia and, coincidentally, a target of
PTHRP signaling in bone development, has been re-
ported to exert an effect at a distance of 950 kb away
from a chromosomal breakpoint (Pfeifer et al. 1999;
Huang et al. 2001). Similarly, expression of POU3F4,
involved in X-linked deafness, can be effected over a
distance of ∼900 kb (de Kok et al. 1996). However,
despite the intriguing possibility that PTHRP might
somehow contribute to the DGAP103 phenotype, par-
ticularly with regard to the advanced bone and dental
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ages, normal peripheral blood levels of PTH and PTHrP
do not support the possibility that position effect exerted
through PTHRP is a contributing factor in the bone
abnormalities.
Certainly, position effects of unknown genes mapping
within a critical interval surrounding the p11.22 break-
point—or even the q14.3 breakpoint—remain possibil-
ities in this novel phenotype. Recently, a novel category
of mammalian genomic sequences more conserved than
protein-encoding sequences has been identified. These
conserved nongenic sequences (CNGs) could be candi-
dates for disruption in chromosomal rearrangements
such as the pericentric inversion in our patient. CNGs
appear to be located in random intergenic regions and
do not share any distance requirements with any pre-
viously characterized regulatory elements (Dermitzakis
et al. 2003). It has been suggested that CNGs could be
involved in either cis or trans chromosomal interactions
affecting genome function and regulation (Dermitzakis
et al. 2004). To date, CNGs have only been studied for
human chromosome 21. It is worth noting, however,
that the region surrounding the p11.22 breakpoint in
DGAP103 also shares significant homology with the mu-
rine genome and could harbor undiscovered coding or
noncoding elements such as CNGs.
In summary, we report an 8-year-old male with a de
novo chromosomal inversion resulting in aberrant adi-
posity and somatic overgrowth. These phenotypic fea-
tures are attributed to a constitutional disruption of
HMGA2—to our knowledge, an event not previously
observed in humans. This phenotype, particularly with
respect to overgrowth and lipomagenesis, is strikingly
similar to that of murine models expressing truncated
Hmga2 transcripts. The possibility that HMGA2 par-
ticipates in human bone or tooth development must also
be considered, on the basis of the phenotype of
DGAP103. A pleiotropic effect of HMGA2 in this hu-
man developmental disorder and the potential contri-
bution of any position effect of nearby genetic elements
warrant further study.
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